Navigation Links
Novavax CEO to Present at Lazard Capital Markets 5th Annual Healthcare Conference
Date:11/12/2008

ROCKVILLE, Md., Nov. 12 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer, will be presenting at the Lazard Capital Markets 5th Annual Healthcare Conference at 3:00 pm. (EST) on November 19, 2008 at the St. Regis Hotel, New York city. Dr. Singhvi will provide an overview of the company's strategy, research and development progress. A link to the live presentation can be accessed via the Company website at http://www.novavax.com. An archive of the presentation will be available one hour after the event on the Novavax website for 90 days.

ABOUT NOVAVAX

Novavax, Inc. (Nasdaq: NVAX) is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at http://www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
2. Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
3. Novavax CEO to Present at BIO Investor Forum 2008
4. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
5. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
6. Novavax Announces Closing of $18 Million Registered Direct Offering
7. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
8. Novavax to Join Russell 3000 Index
9. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
10. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
11. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... and NEW YORK , ... Lumeon , a leading digital health company, ... a provider of telemedicine and remote patient monitoring, ... for telemedicine reimbursements.  DN Telehealth ... patients, in real-time, extending consultations beyond a physical ...
(Date:2/23/2017)... Atlanta, it seems everyone has a chance to express their ... expressive and dynamic community unlike any other. The businesses that ... With their newest salon in ... on that tradition with a unique, fresh approach to head ... the newest of 13 nationwide locations, each of them well-situated ...
(Date:2/23/2017)... Ind. (PRWEB) , ... February 23, 2017 , ... ... Award during the 12th annual Inventors Recognition Reception at Purdue Research Park ... to a faculty member in recognition of outstanding contributions to, and success with, ...
(Date:2/23/2017)... SAN DIEGO and SAN FRANCISCO ... , a privately-held regenerative medicine company, and Beyond Type ... living with type 1 diabetes, today announced a grant ... develop a functional cure for type 1 and other ... decade, ViaCyte has been developing innovative stem cell-derived cell ...
Breaking Biology Technology:
(Date:2/7/2017)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the latest release of ... and award winning eClinical solution, is now available for ... a proven Software-as-a-Service (SaaS) clinical research technology platform that ... delivers an entire suite of eClinical tools to support ...
(Date:2/6/2017)... DENVER , Feb. 6, 2017 ... national security are driving border authorities to continue ... Acuity reports there are 2143 Automated Border Control ... Kiosks currently deployed at more than 163 ports ... between 2013 to 2016 achieving a combined CAGR ...
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
Breaking Biology News(10 mins):